Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $19

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $17 to $19.